Literature DB >> 16788848

Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Alexander Berndt1, Katharina Anger, Petra Richter, Laura Borsi, Simon Brack, Michela Silacci, Marcus Franz, Heiko Wunderlich, Mieczyslaw Gajda, Luciano Zardi, Dario Neri, Hartwig Kosmehl.   

Abstract

PURPOSE: Through alternative splicing of the extracellular matrix protein tenascin-C (Tn-C) primary transcript nine type III homology repeats can be independently included or omitted. Large, low spliced Tn-C variants (Tn-C(L)) are preferentially expressed during tissue remodelling processes like tumour invasion to modulate cell migration. The study was aimed to evaluate the differential expression of Tn-C splicing domains in urinary bladder carcinoma with respect to the invasive behaviour.
METHODS: The deposition and synthesis of the Tn-C splicing domains A1-D was analysed in 34 urinary bladder carcinomas by semiquantitative immunohistochemistry using domain specific antibodies and by RT-PCR. Results were correlated to tumour stage and grade.
RESULTS: There is a significant increase of Tn-C(L) with higher tumour stage and grade. Immunohistochemistry revealed a more restricted distribution pattern of A1, B, and/or D domain containing Tn-C variants to invasive tumours, tumour vessels, and to destructed muscle. The mRNA expression patterns of the domains A1-A3 are similar among the different carcinomas. Stronger differences exist in the region from the B to D domain. In general, the domains AD1/C are rarely expressed. AD1 domain expression seems to be connected with compact invasion pattern.
CONCLUSION: In urinary bladder carcinoma a differential expression of Tn-C splicing variants exists in dependence of tumour type, vascularization, and invasive behaviour. Therefore, the detection of different Tn-C splicing domains could be useful for assessment of muscle invasion, tumour surveillance, as well as target structures for antibody based tumour detection and therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788848     DOI: 10.1007/s00432-006-0106-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  Design, construction, and characterization of a large synthetic human antibody phage display library.

Authors:  Michela Silacci; Simon Brack; Giulia Schirru; Jessica Mårlind; Anna Ettorre; Adrian Merlo; Francesca Viti; Dario Neri
Journal:  Proteomics       Date:  2005-06       Impact factor: 3.984

2.  Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma.

Authors:  K Emoto; Y Yamada; H Sawada; H Fujimoto; M Ueno; T Takayama; K Kamada; A Naito; S Hirao; Y Nakajima
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

3.  Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae.

Authors:  A J Mighell; J Thompson; W J Hume; A F Markham; P A Robinson
Journal:  Int J Cancer       Date:  1997-07-17       Impact factor: 7.396

4.  Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

Authors:  A Siri; B Carnemolla; M Saginati; A Leprini; G Casari; F Baralle; L Zardi
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

5.  Clinical significance of tenascin-C expression in osteosarcoma: tenascin-C promotes distant metastases of osteosarcoma.

Authors:  M Tanaka; T Yamazaki; N Araki; H Yoshikawa; T Yoshida; T Sakakura; A Uchida
Journal:  Int J Mol Med       Date:  2000-05       Impact factor: 4.101

6.  Value of tenascin-C content and association with clinicopathological parameters in uterine cervical lesions.

Authors:  Huseyin Buyukbayram; Adem Arslan
Journal:  Int J Cancer       Date:  2002-08-20       Impact factor: 7.396

Review 7.  Tenascin and other adhesion-modulating proteins in cancer.

Authors:  R Chiquet-Ehrismann
Journal:  Semin Cancer Biol       Date:  1993-10       Impact factor: 15.707

8.  Human tenascin gene. Structure of the 5'-region, identification, and characterization of the transcription regulatory sequences.

Authors:  R Gherzi; B Carnemolla; A Siri; M Ponassi; E Balza; L Zardi
Journal:  J Biol Chem       Date:  1995-02-17       Impact factor: 5.157

9.  Basement membrane and extracellular interstitial matrix components in bladder neoplasia--evidence of angiogenesis.

Authors:  S Deen; R Y Ball
Journal:  Histopathology       Date:  1994-11       Impact factor: 5.087

10.  Binding of tenascin-C to soluble fibronectin and matrix fibrils.

Authors:  C Y Chung; L Zardi; H P Erickson
Journal:  J Biol Chem       Date:  1995-12-01       Impact factor: 5.157

View more
  14 in total

1.  Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery.

Authors:  Kerstin Galler; Kerstin Junker; Marcus Franz; Julia Hentschel; Petra Richter; Mieczyslaw Gajda; Angela Göhlert; Ferdinand von Eggeling; Regine Heller; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2011-11-11       Impact factor: 4.304

Review 2.  Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies.

Authors:  Andrei Turtoi; Edwin De Pauw; Vincent Castronovo
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

3.  Selection and characterization of tenascin C targeting peptide.

Authors:  Mee Young Kim; Ok Ran Kim; Yong Seok Choi; Heuiran Lee; Keerang Park; Choon-Taek Lee; Keon Wook Kang; Sunjoo Jeong
Journal:  Mol Cells       Date:  2011-12-01       Impact factor: 5.034

4.  Existence of tenascin-C isoforms in rat that contain the alternatively spliced AD1 domain are developmentally regulated during hippocampal development.

Authors:  J Garwood; U Theocharidis; V Calco; A Dobbertin; A Faissner
Journal:  Cell Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.046

Review 5.  Role of Annexin-II in GI cancers: interaction with gastrins/progastrins.

Authors:  Pomila Singh
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

6.  A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Authors:  Alexander Berndt; Robert Köllner; Petra Richter; Marcus Franz; Astrid Voigt; Angela Berndt; Laura Borsi; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl
Journal:  Histochem Cell Biol       Date:  2010-03-17       Impact factor: 4.304

Review 7.  Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.

Authors:  Alexander Berndt; Petra Richter; Hartwig Kosmehl; Marcus Franz
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

8.  The role of structural extracellular matrix proteins in urothelial bladder cancer (review).

Authors:  Andrea Brunner; Alexandar Tzankov
Journal:  Biomark Insights       Date:  2007-11-05

9.  B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Authors:  Petra Richter; Markus Tost; Marcus Franz; Annelore Altendorf-Hofmann; Kerstin Junker; Laura Borsi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-27       Impact factor: 4.553

Review 10.  Tenascin-C and integrins in cancer.

Authors:  Toshimichi Yoshida; Tatsuya Akatsuka; Kyoko Imanaka-Yoshida
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.